{"shortAnswer":"GHK-Cu is split by route. For uses other than injection, such as on the skin, it is in Category 1: a pharmacy may use it while FDA decides. Injected GHK-Cu is in limbo, and no pharmacy may lawfully make it. The evidence grade is limited-human: a few small skin trials, and little human data on injection.","url":"https://peptideindex.ai/compound/ghk-cu","status":"category-1","statusCheckedAt":"2026-10-25T23:57:23.798Z","statusStale":false,"regulatoryAsOf":"2026-10-25","verified":"2026-10-26T03:03:14.806Z","primarySourceUrl":"https://www.fda.gov/media/94155/download","clinicallyReviewed":false,"notice":"Information, not medical advice.","id":"b83cd93f-c61c-404a-8711-65f02969a1af","object":"compound","slug":"ghk-cu","name":"GHK-Cu","attrs":{"name":"GHK-Cu","class":"healing-and-repair","access":[{"type":"lawful-compounding","detail":"For routes other than injection, such as on the skin, GHK-Cu is in Category 1. A licensed pharmacy may make it while FDA decides, if it meets the policy's conditions. Injected GHK-Cu has no legal route.","source_url":"https://www.fda.gov/media/94155/download"}],"trials":[{"nct":"NCT07437586","url":"https://clinicaltrials.gov/study/NCT07437586","phase":"Phase 2","title":"Topical GHK-Cu Gel for Acute Skin Wound Healing","status":"recruiting","sponsor":"Hudson Biotech","countries":["China"],"us_states":[]}],"aliases":["tripeptide-copper complex","glycyl-L-histidyl-L-lysine-Cu2+"],"summary":"A small peptide found in human blood, bound to copper. It has long been sold in skin creams. Some people now inject it.","citations":[{"n":1,"url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2"},{"n":2,"url":"https://www.fda.gov/media/94155/download","tier":"primary","type":"regulatory","title":"FDA: categories of bulk drug substances nominated under section 503A, list updated 14 May 2026"},{"n":3,"url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances used in compounding under section 503A"},{"n":4,"url":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee","tier":"primary","type":"regulatory","title":"FDA: Pharmacy Compounding Advisory Committee meeting before the end of February 2027"},{"n":5,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020","tier":"primary","type":"regulatory","title":"FDA warning letter to a compounding pharmacy, 1 April 2020"},{"n":6,"url":"https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/","tier":"legal-analysis","type":"legal-analysis","title":"McDermott Will & Schulte: what the July 2026 committee votes on peptides mean"},{"n":7,"url":"https://www.goodwinlaw.com/en/insights/blogs/2026/05/fda-signals-potentially-evolving-stance-toward-compounding-of-certain-peptides","tier":"legal-analysis","type":"legal-analysis","title":"Goodwin: FDA signals a possible change in its stance on compounding some peptides"},{"n":8,"url":"https://www.sheppard.com/insights/blogs/fda-balances-peptide-policy-with-enforcement-against-unlawful-peptide-sellers","tier":"legal-analysis","type":"legal-analysis","title":"Sheppard Mullin: FDA pairs its peptide policy with action against unlawful sellers"},{"n":9,"url":"https://pubmed.ncbi.nlm.nih.gov/16847171/","tier":"peer-reviewed","type":"rct","title":"GHK-Cu skin care after laser skin treatment, randomized trial in 13 people, 2006"},{"n":10,"url":"https://pubmed.ncbi.nlm.nih.gov/1495150/","tier":"peer-reviewed","type":"rct","title":"Copper peptide cream for leg ulcers, randomized trial in 86 people, 1992"},{"n":11,"url":"https://pubmed.ncbi.nlm.nih.gov/8227353/","tier":"peer-reviewed","type":"animal","title":"GHK-Cu injected into wound chambers in rats, 1993"},{"n":12,"url":"https://pubmed.ncbi.nlm.nih.gov/25731775/","tier":"peer-reviewed","type":"animal","title":"GHK-Cu injected into the knee after ligament surgery in rats, 2015"},{"n":13,"url":"https://pubmed.ncbi.nlm.nih.gov/31809714/","tier":"peer-reviewed","type":"animal","title":"GHK-Cu in mice with lung scarring, 2020"},{"n":14,"url":"https://pubmed.ncbi.nlm.nih.gov/42619529/","tier":"peer-reviewed","type":"systematic-review","title":"Systematic review: GHK-Cu in aesthetic medicine, 2026"},{"n":15,"url":"https://pubmed.ncbi.nlm.nih.gov/42787770/","tier":"peer-reviewed","type":"systematic-review","title":"Systematic review: how GHK-Cu acts and the case for more trials, 2026"},{"n":16,"url":"https://pubmed.ncbi.nlm.nih.gov/39963574/","tier":"peer-reviewed","type":"reference","title":"Review: GHK on the skin against wrinkles, 2025"},{"n":17,"url":"https://pubmed.ncbi.nlm.nih.gov/41476424/","tier":"peer-reviewed","type":"reference","title":"Review: injectable peptides for bone, joint and sports doctors, 2026"},{"n":18,"url":"https://pubmed.ncbi.nlm.nih.gov/41966639/","tier":"peer-reviewed","type":"reference","title":"Review: approved and unapproved peptides for injuries and sport, 2026"},{"n":19,"url":"https://clinicaltrials.gov/study/NCT07437586","tier":"primary","type":"reference","title":"ClinicalTrials.gov: topical GHK-Cu gel for skin wound healing, NCT07437586"},{"n":20,"url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe","tier":"established-news","type":"reference","title":"NPR: the copper peptide trend has gone from creams to injections, 7 September 2026"},{"n":21,"url":"https://www.raps.org/resource/fda-considers-adding-a-dozen-peptides-to-its-bulk-drug-compounding-list.html","tier":"established-news","type":"reference","title":"RAPS: FDA considers adding a dozen peptides to its compounding list"},{"n":22,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026","tier":"primary","type":"regulatory","title":"FDA warning letter to a seller of research-use peptides, 24 August 2026"}],"known_risks":["FDA warns that injected GHK-Cu made by a pharmacy may set off the immune system. The peptide can clump and can carry impurities [^1].","FDA says there are few data in people on the safety of injected GHK-Cu [^1].","A clinician told NPR of patients with skin irritation, infections and high liver tests after injecting it on their own [^20]. It is not clear whether the copper peptide or something else in the product caused this [^20].","Doctors told NPR that injected products bought online come with no assurance of what is in them [^20]."],"short_answer":"GHK-Cu is split by route. For uses other than injection, such as on the skin, it is in Category 1: a pharmacy may use it while FDA decides. Injected GHK-Cu is in limbo, and no pharmacy may lawfully make it. The evidence grade is limited-human: a few small skin trials, and little human data on injection.","evidence_grade":"limited-human","open_questions":["Nobody knows what injected GHK-Cu does in people. No published human study has shown its effects or its safety [^20].","Whether GHK-Cu helps the skin is not settled. Small trials in people disagree [^9] [^14].","How much GHK-Cu passes through the skin is not well known [^16] [^15].","About a third of GHK-Cu studies share authors who have long held business interests in the field, a 2026 review notes [^15].","FDA has not set a date for its committee to meet on GHK-Cu [^4]. FDA has not decided whether to add it to the federal list [^2]."],"section_routes":"For routes other than injection, a licensed pharmacy may make GHK-Cu under FDA's Category 1 policy [^2] [^3]. FDA says it does not plan to act against that compounding when the policy's conditions are met [^3]. This covers forms such as those used on the skin. It does not cover injection [^2].\n\nThere is no legal way to get injected GHK-Cu in the US today [^1] [^2]. No approved drug contains GHK-Cu [^5]. A pharmacy may use a substance like it only if it is in an approved drug or on FDA's list [^3].\n\nThe one open trial of GHK-Cu we found tests a skin gel, and its only site is in China [^19]. Any open trial would appear in the trials block below, with the date the registry was last checked.","status_by_route":[{"route":"Routes other than injection, such as on the skin","status":"category-1","source_url":"https://www.fda.gov/media/94155/download"},{"route":"Injection","status":"limbo","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"regulatory_as_of":"2026-10-25","section_channels":"NPR reports that many people buy injectable GHK-Cu from online sellers [^20]. Doctors told NPR there is no assurance of what is in those products [^20]. FDA has warned a seller of research-use peptides that a \"research use only\" label does not stop a product from being a drug [^22]. That letter did not name GHK-Cu [^22].\n\nPharmacies are the other channel that a federal record names [^5]. In 2020, FDA warned a compounding pharmacy that its GHK-Cu products did not meet the rules for compounding [^5]. NPR also reports that a clinic offers GHK-Cu injections made by a US pharmacy, despite the limits [^20]. FDA warns that injected GHK-Cu may set off the immune system and may carry impurities [^1].","section_evidence":"The evidence grade is limited-human: the few trials in people tested products on the skin [^15]. No published human study shows that injecting it is safe [^20]. A study on the skin says nothing about what an injection does.\n\nSkin trials in people: in a 2006 trial, 13 people used skin care with or without GHK-Cu after laser treatment around the mouth [^9]. Blinded reviewers found no difference in redness, wrinkles or skin quality [^9]. People who used GHK-Cu did rate their skin as better [^9]. In a 1992 trial of 86 people with leg ulcers, a tripeptide copper cream did no better than a cream with no drug [^10]. The study summary does not say which tripeptide it used [^10]. A 2026 review found only two randomized trials of GHK-Cu for looks among 20 studies [^14]. It reports that GHK-Cu reduced wrinkle depth compared with controls [^14]. Another 2026 review says most human trials are small and test face creams [^15].\n\nInjection in animals: in rats, GHK-Cu injected into small chambers under the skin raised collagen and other wound tissue [^11]. In rats after knee ligament surgery, GHK-Cu injected into the knee helped at 6 weeks but not at 12 weeks [^12]. In mice with lung scarring, GHK-Cu injected into the belly reduced the scarring [^13]. A result in an animal does not show what happens in people.\n\nA 2026 review for sports doctors found no clinical data for GHK-Cu in muscle, bone or joint problems [^17]. A recruiting trial is testing a GHK-Cu gel on small skin wounds in healthy adults [^19]. Its only site is in China [^19].","regulatory_status":"category-1","section_what_it_is":"GHK-Cu is a small peptide bound to copper [^11]. The peptide, called GHK, is a chain of three amino acids [^20]. A chemist first found it in human blood in the early 1970s [^20]. Its full chemical name is glycyl-L-histidyl-L-lysine-Cu2+ [^11].\n\nCopper peptide creams and serums have been sold for skin care for decades [^20]. More recently, many people have started to inject it under the skin [^20]. FDA treats the injected form and other forms differently [^1] [^2].","section_is_it_legal":"GHK-Cu is split by route. For routes other than injection, it is in Category 1: FDA's list of substances pharmacies may use while FDA decides [^2] [^3]. That is not approval, and FDA is still deciding whether to add it to the federal list. Injected GHK-Cu is in limbo: it came off Category 2 and was not added to Category 1 [^1] [^2]. That does not make it lawful to compound. Checked 25 October 2026.\n\nCategory 2 is FDA's list of substances that may raise significant safety risks [^1]. For Category 1, FDA says it does not plan to act against a pharmacy that meets the policy's conditions [^3]. That is a choice not to act, not approval of GHK-Cu as a drug [^3].\n\nIn April 2026, the groups that nominated GHK-Cu withdrew. FDA then took the injected form off Category 2 and the other forms off Category 1 [^1] [^2] [^6]. In May 2026, one group said it meant to withdraw only the injected form [^2]. FDA then put the other forms back in Category 1 [^2]. Removal from Category 2 does not by itself let pharmacies use a substance [^7].\n\nFDA says its Pharmacy Compounding Advisory Committee will discuss GHK-Cu before the end of February 2027 [^4] [^2]. FDA has posted no date for that meeting [^4]. A news report on the injected form says the committee will look at it then [^20]. The committee gives advice only, and FDA decides by writing a rule [^6].","unofficial_channels":[{"type":"research-use-seller","what_it_is":"Websites that sell injectable GHK-Cu straight to the public.","enforcement":[{"date":"2026-08-24","text":"FDA warning letter to a seller of research-use peptides: a research-use label did not stop its products from being unapproved drugs. The letter does not name GHK-Cu.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026"}],"legal_position":{"text":"FDA says a research-use label does not stop a product meant for people from being a drug. An unapproved new drug may not be sold across state lines.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026"},"documented_risks":[{"text":"Doctors told NPR there is no assurance of what is in injectable GHK-Cu bought online.","source_url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe"},{"text":"FDA warns that injected GHK-Cu may set off the immune system and may carry impurities.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}]},{"type":"compounding-outside-the-rules","what_it_is":"Injected GHK-Cu made by a pharmacy, a form that is not in Category 1.","enforcement":[{"date":"2020-04-01","text":"FDA warning letter to a compounding pharmacy: GHK-Cu was among bulk substances that made its products ineligible under section 503A.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"},{"date":"2026-05-14","text":"FDA's 503A category list, updated 14 May 2026, puts GHK-Cu in Category 1 only for routes other than injection.","source_url":"https://www.fda.gov/media/94155/download"}],"legal_position":{"text":"Only forms of GHK-Cu given by routes other than injection are in Category 1. FDA's list leaves out injected GHK-Cu.","source_url":"https://www.fda.gov/media/94155/download"},"documented_risks":[{"text":"FDA warns that injected GHK-Cu made by a pharmacy may set off the immune system. FDA says there are few data in people on its safety.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"text":"A clinician told NPR of patients with infections and high liver tests after injecting GHK-Cu.","source_url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe"}]}]},"provenance":{"name":{"fact_id":"1642f36e-d339-4f96-a66e-434d66e9aa5e","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-25T22:01:55.068Z","checked_at":"2026-10-25T23:57:23.823Z","confidence":1,"stale":false},"class":{"fact_id":"7e8b8392-6192-4bec-a658-bf30d2bbdc51","source_url":"https://pubmed.ncbi.nlm.nih.gov/8227353/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:36:28.986Z","checked_at":"2026-10-25T23:57:23.828Z","confidence":1,"stale":false},"access":{"fact_id":"dc451e1f-982a-4a49-9a7c-bd7298cb6e14","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-25T22:01:55.068Z","checked_at":"2026-10-25T23:57:23.788Z","confidence":1,"stale":false},"trials":{"fact_id":"300a304c-2301-4041-9a82-130b1be2f0fa","source_url":"https://clinicaltrials.gov/api/v2/studies?query.intr=GHK-Cu+gel+OR+Copper%28II%29-peptide+complex&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","source_type":"primary","captured_at":"2026-10-25T23:57:29.095Z","checked_at":"2026-10-25T23:57:29.095Z","confidence":1,"stale":false},"aliases":{"fact_id":"64595ce8-c417-4fc7-90bb-7a2e0e2f80e8","source_url":"https://pubmed.ncbi.nlm.nih.gov/8227353/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:36:28.986Z","checked_at":"2026-10-25T23:57:23.826Z","confidence":1,"stale":false},"summary":{"fact_id":"4f8bbdc3-9de3-4a61-b7d4-a2ab48c01806","source_url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe","source_type":"established-news","captured_at":"2026-10-25T22:36:33.696Z","checked_at":"2026-10-25T23:57:23.830Z","confidence":1,"stale":false},"citations":{"fact_id":"b082162e-4be9-4603-a6df-3dd8c954dc87","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-25T22:01:55.068Z","checked_at":"2026-10-25T23:57:23.838Z","confidence":1,"stale":false},"known_risks":{"fact_id":"ede199f7-35e9-40a7-8c91-61c364468606","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-25T23:57:23.817Z","confidence":1,"stale":false},"short_answer":{"fact_id":"4e827fb5-e163-4bfb-adcd-38c7b70aec1f","source_url":"https://peptideindex.ai/methodology#short-answer","source_type":"reference","captured_at":"2026-10-25T00:14:44.418Z","checked_at":"2026-10-25T23:57:23.832Z","confidence":1,"stale":false,"label":"our assessment"},"evidence_grade":{"fact_id":"7bf4e6fa-484f-4ff5-81c0-8c67beac2600","source_url":"https://peptideindex.ai/methodology#evidence-grade","source_type":"reference","captured_at":"2026-10-25T00:14:45.193Z","checked_at":"2026-10-25T23:57:23.815Z","confidence":1,"stale":false,"label":"our assessment"},"open_questions":{"fact_id":"6b13c2a9-35af-4df9-a997-c9eb4bd9177e","source_url":"https://pubmed.ncbi.nlm.nih.gov/42787770/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:36:31.349Z","checked_at":"2026-10-25T23:57:23.839Z","confidence":1,"stale":false},"section_routes":{"fact_id":"443666d9-1dfd-4afe-b805-1153ebad4ac3","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-25T22:01:55.068Z","checked_at":"2026-10-25T23:57:23.833Z","confidence":1,"stale":false},"status_by_route":{"fact_id":"7556d7cb-1be0-4e8a-b622-5a6fb8f6f690","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-25T22:01:55.068Z","checked_at":"2026-10-25T23:57:23.805Z","confidence":1,"stale":false},"regulatory_as_of":{"fact_id":"51ed06b0-71af-4a4e-8d7d-3d8c4bd0ccc6","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-25T22:01:55.068Z","checked_at":"2026-10-25T23:57:23.812Z","confidence":1,"stale":false},"section_channels":{"fact_id":"498a8f54-6989-470b-8dc9-67a6a505b82c","source_url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe","source_type":"established-news","captured_at":"2026-10-25T22:36:33.696Z","checked_at":"2026-10-26T03:03:14.806Z","confidence":1,"stale":false},"section_evidence":{"fact_id":"df195f6d-0d06-4577-9259-aafbf8935518","source_url":"https://pubmed.ncbi.nlm.nih.gov/42787770/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:36:31.349Z","checked_at":"2026-10-25T23:57:23.803Z","confidence":1,"stale":false},"regulatory_status":{"fact_id":"4004cb78-2ca8-4907-a989-e973e02d15ee","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-25T22:01:55.068Z","checked_at":"2026-10-25T23:57:23.798Z","confidence":1,"stale":false},"section_what_it_is":{"fact_id":"d678f7cd-17ca-40c3-90cf-b0d61734e036","source_url":"https://pubmed.ncbi.nlm.nih.gov/8227353/","source_type":"peer-reviewed","captured_at":"2026-10-25T22:36:28.986Z","checked_at":"2026-10-25T23:57:23.819Z","confidence":1,"stale":false},"section_is_it_legal":{"fact_id":"4414a07a-be64-455e-9a60-7fc147fa37de","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-25T22:01:55.068Z","checked_at":"2026-10-25T23:57:23.820Z","confidence":1,"stale":false},"unofficial_channels":{"fact_id":"295dc637-c438-4589-8fc2-4c85d7f522d6","source_url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe","source_type":"established-news","captured_at":"2026-10-25T22:36:33.696Z","checked_at":"2026-10-25T23:57:23.809Z","confidence":1,"stale":false}},"citationsBySection":{"known_risks":[{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":20,"title":"NPR: the copper peptide trend has gone from creams to injections, 7 September 2026","url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe"}],"open_questions":[{"n":20,"title":"NPR: the copper peptide trend has gone from creams to injections, 7 September 2026","url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe"},{"n":9,"title":"GHK-Cu skin care after laser skin treatment, randomized trial in 13 people, 2006","url":"https://pubmed.ncbi.nlm.nih.gov/16847171/"},{"n":14,"title":"Systematic review: GHK-Cu in aesthetic medicine, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42619529/"},{"n":16,"title":"Review: GHK on the skin against wrinkles, 2025","url":"https://pubmed.ncbi.nlm.nih.gov/39963574/"},{"n":15,"title":"Systematic review: how GHK-Cu acts and the case for more trials, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42787770/"},{"n":4,"title":"FDA: Pharmacy Compounding Advisory Committee meeting before the end of February 2027","url":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee"},{"n":2,"title":"FDA: categories of bulk drug substances nominated under section 503A, list updated 14 May 2026","url":"https://www.fda.gov/media/94155/download"}],"section_routes":[{"n":2,"title":"FDA: categories of bulk drug substances nominated under section 503A, list updated 14 May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":3,"title":"FDA: bulk drug substances used in compounding under section 503A","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":5,"title":"FDA warning letter to a compounding pharmacy, 1 April 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"},{"n":19,"title":"ClinicalTrials.gov: topical GHK-Cu gel for skin wound healing, NCT07437586","url":"https://clinicaltrials.gov/study/NCT07437586"}],"section_channels":[{"n":20,"title":"NPR: the copper peptide trend has gone from creams to injections, 7 September 2026","url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe"},{"n":22,"title":"FDA warning letter to a seller of research-use peptides, 24 August 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026"},{"n":5,"title":"FDA warning letter to a compounding pharmacy, 1 April 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"section_evidence":[{"n":15,"title":"Systematic review: how GHK-Cu acts and the case for more trials, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42787770/"},{"n":20,"title":"NPR: the copper peptide trend has gone from creams to injections, 7 September 2026","url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe"},{"n":9,"title":"GHK-Cu skin care after laser skin treatment, randomized trial in 13 people, 2006","url":"https://pubmed.ncbi.nlm.nih.gov/16847171/"},{"n":10,"title":"Copper peptide cream for leg ulcers, randomized trial in 86 people, 1992","url":"https://pubmed.ncbi.nlm.nih.gov/1495150/"},{"n":14,"title":"Systematic review: GHK-Cu in aesthetic medicine, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42619529/"},{"n":11,"title":"GHK-Cu injected into wound chambers in rats, 1993","url":"https://pubmed.ncbi.nlm.nih.gov/8227353/"},{"n":12,"title":"GHK-Cu injected into the knee after ligament surgery in rats, 2015","url":"https://pubmed.ncbi.nlm.nih.gov/25731775/"},{"n":13,"title":"GHK-Cu in mice with lung scarring, 2020","url":"https://pubmed.ncbi.nlm.nih.gov/31809714/"},{"n":17,"title":"Review: injectable peptides for bone, joint and sports doctors, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41476424/"},{"n":19,"title":"ClinicalTrials.gov: topical GHK-Cu gel for skin wound healing, NCT07437586","url":"https://clinicaltrials.gov/study/NCT07437586"}],"section_what_it_is":[{"n":11,"title":"GHK-Cu injected into wound chambers in rats, 1993","url":"https://pubmed.ncbi.nlm.nih.gov/8227353/"},{"n":20,"title":"NPR: the copper peptide trend has gone from creams to injections, 7 September 2026","url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":2,"title":"FDA: categories of bulk drug substances nominated under section 503A, list updated 14 May 2026","url":"https://www.fda.gov/media/94155/download"}],"section_is_it_legal":[{"n":2,"title":"FDA: categories of bulk drug substances nominated under section 503A, list updated 14 May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":3,"title":"FDA: bulk drug substances used in compounding under section 503A","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, including those withdrawn from Category 2","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":6,"title":"McDermott Will & Schulte: what the July 2026 committee votes on peptides mean","url":"https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/"},{"n":7,"title":"Goodwin: FDA signals a possible change in its stance on compounding some peptides","url":"https://www.goodwinlaw.com/en/insights/blogs/2026/05/fda-signals-potentially-evolving-stance-toward-compounding-of-certain-peptides"},{"n":4,"title":"FDA: Pharmacy Compounding Advisory Committee meeting before the end of February 2027","url":"https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee"},{"n":20,"title":"NPR: the copper peptide trend has gone from creams to injections, 7 September 2026","url":"https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe"}]},"channelsOpener":"This section describes what happens and is not a recommendation.","sources":["https://clinicaltrials.gov/api/v2/studies?query.intr=GHK-Cu+gel+OR+Copper%28II%29-peptide+complex&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","https://peptideindex.ai/methodology#evidence-grade","https://peptideindex.ai/methodology#short-answer","https://pubmed.ncbi.nlm.nih.gov/42787770/","https://pubmed.ncbi.nlm.nih.gov/8227353/","https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","https://www.fda.gov/media/94155/download","https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe"],"verified_at":"2026-10-26T03:03:14.806Z","published_at":"2026-10-26T03:03:16.850Z","parent":null,"children":[],"snapshots":{"trials":{"snapshot_at":"2026-10-25T23:57:29.095Z","stale":false,"notice":"A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record."}}}